title: Biodegradable polymer releasing antibiotic developed for drainage catheter of cerebrospinal fluid: in vitro results.
abstract: The authors developed a biodegradable polymer that releases an antibiotic (nalidixic acid) slowly and continuously, for prevention of catheter-induced infection during drainage of cerebrospinal fluid. We investigated the in vitro antibiotic releasing characteristics and bacterial killing effects of the new polymer against E. coli. The novel fluoroquinolone polymer was prepared using diisopropylcarbodiimide, poly (e-capro-lactone) diol, and nalidixic acid. FT-IR, mass spectrometry, and elemental analysis proved that the novel antibacterial polymer was prepared successfully without any side products. Negative MS showed that the released drug has a similar molecular weight (M.W.=232, 350) to pure drug (M.W.=232). In high pressure liquid chromatography, the released drug and drug-oligomer showed similar retention times (about 4.5-5 min) in comparison to pure drug (4.5 min). The released nalidixic acid and nalidixic acid derivatives have antibacterial characteristics against E. Coli, Staphylococcus aureus, and Salmonella typhi, of more than 3 months duration. This study suggests the possibility of applying this new polymer to manufacture drainage catheters that resist catheter-induced infection, by delivering antibiotics for a longer period of more than 1 month.
authors.affiliation: Department of Neurosurgery, School of Medicine, Ajou University, Suwon 442-721, Korea.
authors.forename: Song Yup
authors.initials: SY
authors.lastname: Han
authors.forename: Soo Han
authors.initials: SH
authors.lastname: Yoon
authors.forename: Ki Hong
authors.initials: KH
authors.lastname: Cho
authors.forename: Han Jin
authors.initials: HJ
authors.lastname: Cho
authors.forename: Jeong Ho
authors.initials: JH
authors.lastname: An
authors.forename: Young Sin
authors.initials: YS
authors.lastname: Ra
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001673:Biodegradation, Environmental; D018441:Biofilms; D002404:Catheterization / Q000009:adverse effects*; D002555:Cerebrospinal Fluid / Q000502:physiology*; D002851:Chromatography, High Pressure Liquid; D004322:Drainage / Q000009:adverse effects*; D016503:Drug Delivery Systems; D006801:Humans; D013058:Mass Spectrometry; D009268:Nalidixic Acid / Q000008:administration & dosage*; D011108:Polymers / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D011108:Polymers; D009268:Nalidixic Acid